I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from | Terms/Details (Date) |
| | |||
Aclara BioSciences Inc. (ACLA) |
Genentech Inc. (NYSE:DNA) |
Expanded eTag assay collaboration |
Genentech will make milestone payments as part of the expansion to study genes, proteins and cell-based antigens using the eTag Assay System (4/30) |
|
|
|
|
Aldevron LLC* |
Prometic Life Sciences Inc. (Canada; TSE:PLI) |
Expanded collaboration to develop and market a new technology for the purification of gene therapy and DNA vaccine products |
Financial terms were not disclosed (5/1) |
|
|
|
|
Arius Research |
Protein Design Labs Inc. (PDLI) |
Expanded collaboration for research of anticancer antibodies |
Arius will be paid an up-front technology access fee for research and generation of the antibodies; PDL will continue preclinical development and will have the option to license a number of the antibodies for clinical development; Arius will receive licensing fees, milestone payments and royalties (6/17) |
|
|
|
|
Genaissance Pharmaceuticals Inc. (GNSC) |
Prometheus Laboratories Inc.* |
Expanded agreement under which Prometheus licensed rights from Genaissance to a thiopurine S-methyl-transfease diagnostic test |
The agreement now includes a broader field of use; Genaissance received an up-front license fee from Prometheus and would receive royalties on sales (5/16) |
|
|
|
|
Neurotech SA* (France) |
NsGene A/S* (Denmark) |
Expanded license agreement that grants NsGene a worldwide exclusive license to encapsulated cell technology for the nervous system |
The agreement replaces prior agreements between the parties, simplifies the division of fields and eliminates the cross-royalty obligations (5/9) |
|
|
|
|
Transgenomic |
Geron Corp. (GERN) |
Expanded licensing agreement covering the manufacture of phosphoramidate and thiophosphoramidate oligonucleotides |
Transgenomic gains rights to the patent estate acquired by Geron in 2002 to manufacture phosphoramidate-based oligonucleotides, as well as chemical building blocks required for their synthesis, for use in diagnostic and therapeutic applications; Geron will receive royalties (6/4) |
|
|
|
|
Valentis Inc. |
DSM Biologics* (the Netherlands) |
Revised agreement regarding the financial terms of the agreement licensing Valentis' plasmid DNA manufacturing technology |
The deal was modified to add a royalty to Valentis, in addition to a previous profit-sharing arrangement, and also eliminated about $1.1M of Valentis' accrued liabilities and included a net payment of about $600,000 to Valentis (6/16) |
|
|
|
|
XOMA Ltd. (XOMA) |
Millennium Pharmaceuticals Inc. (MLNM) |
Amended agreement concerning the financing arrangement as part of a collaboration on MLN01 and CAB-2 for certain vascular inflammation indications |
Millennium committed to purchase up to $50M worth of common shares over a three-year period; now, an extension of the maturity date of the $5M outstanding convertible loan from May to February 2004 has been added; also, XOMA's decision on whether to sell the remaining $37.5M worth of common shares from three option dates over the next 12 months was rescheduled to six option dates over the next 21 months (5/21) |
|
|
|
|
Zentaris (subsidiary of AEterna Laboratories Inc.; Canada; AELA; TSE:AEL) |
Serono SA (Switzerland; NYSE:SRA) |
Expanded license agreement related to Cetrotide for worldwide marketing rights, except Japan |
Zentaris will receive a signature fee and fixed annual payments until 2010, followed by royalties; Zentaris will supply Serono with the finished product at a fixed price; Serono received a perpetual fully paid license upon expiry of the last relevant patent held by Zentaris (6/18) |
|
|
|
|
II. TERMINATED AGREEMENTS | |||
ICOS Corp. |
Biogen Inc. (BGEN) |
Terminated agreement in which ICOS regained full rights to a leukocyte function-associated antigen-1antagonist studied in psoriasis |
The rights were returned following disappointing results in a Phase IIa trial (6/6) |
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | |||
